Journal of Immunological Methods?

The Journal of Immunological Methods is a quarterly peer-reviewed periodical established in 1974 at the Infectious Disease Research Centre in Cambridge to standardize measurement protocols for serum therapy trials. It emerged from the recognition that clinical evaluation of passive immunization required statistical methods fundamentally different from those used for chemical treatment, where patients either improved rapidly or declined to death. In the absence of reliable systemic azo drugs effective against polymicrobial infection, the journal's core mission became documenting survival curves, serum potency assays, animal immunization regimens, and the longitudinal tracking of bacterial clearance from blood.

The founding editorial board included Dorothy Umezaki, then at the Infectious Disease Research Centre after her collaboration with James Halloway on the Halloway-Umezaki method, alongside Cambridge biostatisticians and bacteriologists from the Pasteur Institute. The journal's first editor, Malcolm Ashford, established that each contribution must report complete patient survival data using the Kaplan-Meier estimator, a statistical method adapted from industrial reliability testing for use in conditions where treatment outcome was measured in months and years rather than days. This requirement proved controversial. Serum therapy outcomes varied widely by patient age, underlying bacterial species, and the specific animal source of the serum, and the early volumes contain exchanges between researchers asserting that raw survival statistics concealed mechanistic understanding of how passive immunization worked.

The journal's early volumes focused on practical challenges that characterized serum therapy research. Contributors documented optimal immunization schedules for horses, cattle, and rabbits to maximize antibody titres. Issues addressed contamination in serum collection, shelf-life stability of frozen serum stocks, the logistics of the International Serum Registry coordinating biological supplies across nations, and protocols for measuring neutralizing antibody potency against specific bacterial strains. A 1976 special issue documented the serum farms supplying the Cambridge centre and others across Europe, mapping the production capacity available for scaled clinical trials.

By the early 1980s, the Journal of Immunological Methods had become the principal venue for reporting data on the relative efficacy of different serum sources against endocarditis, meningitis, and bacteraemia. The journal published the first systematic comparison of outcomes using horse serum versus bovine sources, data that influenced Geneva Sanitary Bureau recommendations on serum procurement. Contributors included researchers from the Institute for the History of Bacteriology in Berlin, who used the journal to publish statistical re-analysis of post-war hospital records, establishing epidemiological baselines for what untreated infection had cost before serum therapy became clinically available.

The journal maintained strict independence from Bayer AG, the dominant manufacturer of azo drugs, though this boundary occasionally created editorial tension. In 1979, the Editorial Board declined a submission arguing for chemical-serum combination therapy without sufficient statistical support, a decision that drew criticism from researchers funded by Bayer's research division. The editorial response asserted that in the absence of reliable antimicrobial chemotherapy, the journal could not publish claims of synergy unsupported by survival data. This stance established the publication's credibility with clinicians who relied on it to evaluate treatment decisions when both options—chemical sulfonamides of limited efficacy or serum therapy of uncertain but measurable benefit—carried genuine risk.

By 1990, the journal had published over 600 articles and become the standard reference for institutional protocols in clean wards across North America and Europe. Its pages documented not only serum therapy but also the statistical foundations of asepsis maximalism itself: articles on infection rates as functions of ward architecture, on contamination likelihood in different surgical scenarios, on the economics of disposable versus sterilized equipment. The journal thus became an archive of the entire approach to bacterial disease that had evolved in the absence of chemical cure.

The measurement of serum potency must be conducted blind to patient outcome, with animal and clinical assays run in parallel. Any published report lacking complete survival follow-up or animal source documentation will be returned for revision.

— Editorial Policy, Journal of Immunological Methods, 1975

The journal's influence on clinical decision-making remained substantial but circumscribed. Editors and readers understood that serum therapy outcomes, while measurable, remained probabilistic: a given patient's survival depended not only on serum choice but on the particular bacterial strain, the state of the patient's own immune response, and the timing of intervention. The journal published these uncertainties without resolution, establishing statistical ranges and reporting frequency distributions rather than recommending universal protocols. This tolerance for irreducible variation shaped clinical practice in the Long Sepsis, where infection treatment was fundamentally an act of informed choice among imperfect options rather than the application of a certain cure.